Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cellectar Biosciences Inc is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectar Biosciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$0.92|
|52-week range||$0.81 - $2.98|
|50-day moving average||$0.97|
|200-day moving average||$1.23|
|Wall St. target price||$5.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||7.89%|
|1 month (2021-09-16)||-7.36%|
|3 months (2021-07-16)||-15.86%|
|6 months (2021-04-16)||-35.42%|
|1 year (2020-10-16)||-25.44%|
|2 years (2019-10-16)||-43.04%|
|3 years (2018-10-16)||2.75|
|5 years (2016-10-14)||2.23|
|Gross profit TTM||$0|
|Return on assets TTM||-35.09%|
|Return on equity TTM||-62.25%|
|Market capitalisation||$51.9 million|
TTM: trailing 12 months
There are currently 1.0 million Cellectar Biosciences shares held short by investors – that's known as Cellectar Biosciences's "short interest". This figure is 4.2% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Cellectar Biosciences shares can be evaluated.
Cellectar Biosciences's "short interest ratio" (SIR) is the quantity of Cellectar Biosciences shares currently shorted divided by the average quantity of Cellectar Biosciences shares traded daily (recently around 762303.64963504). Cellectar Biosciences's SIR currently stands at 1.37. In other words for every 100,000 Cellectar Biosciences shares traded daily on the market, roughly 1370 shares are currently held short.
However Cellectar Biosciences's short interest can also be evaluated against the total number of Cellectar Biosciences shares, or, against the total number of tradable Cellectar Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectar Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cellectar Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0214% of the tradable shares (for every 100,000 tradable Cellectar Biosciences shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellectar Biosciences.
Find out more about how you can short Cellectar Biosciences stock.
We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.
Cellectar Biosciences's shares were split on a 1:10 basis on 16 July 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.
Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $0.81 up to $2.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.6455. This would suggest that Cellectar Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; and IntoCell Inc. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.